[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100146867":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":36,"collaborators":38,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"First AF ablation",null,"Description of the patients experiencing an AF ablation",[13],"Procedure: Ablation of atrial fibrillation",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":10},"PROCEDURE","Ablation of atrial fibrillation",[9],[20],{"name":21,"affiliation":5,"role":22},"Antoine LEENHARDT, MD,PhD","PRINCIPAL_INVESTIGATOR",[24],{"facility":25,"status":10,"city":26,"state":10,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"Service de cardiologie - Hôpital Lariboisière","Paris","75010","France","FR",{"type":31,"coordinates":32},"Point",[33,34],2.3488,48.85341,{"lat":34,"lon":33},{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[39],{"name":40,"class":41},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV","100146867","medical-economical-evaluation-of-the-ablation-by-catheter-of-the-atrial-tissue-in-the-treatment-of-af-100146867",false,"NCT01183091","Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of AF","Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of the Atrial Fibrillation","EVABLAF","Inclusion Criteria:\n\n* Nonspontaneous and ≤90 days) symptomatic and dating of more than 6 months\n* Patient in failure of at least 1 antiarrythmic major (Class Ic or amiodarone) or repeats after at least 1 medicamentous or electric reduction\n* Patient having presented at least 1 episode of F documented by ECG or Holter\n* Patient having a medical history of AF which can be reconstituted retrospectively over the last 12 months\n* Patient currently under anticoagulant treatment by AVK balanced\n\nExclusion Criteria:\n\n* Patient presenting asymptomatic AF\n* Patient presenting AF permanent (90 days)\n* Patient presenting a counter-indication at the anticoagulants by oral way\n* Patient presenting of the antecedents of ablation of AF\n* Patient presenting an intracardiac thrombus\n* Patient presenting reversible AF of cause","ALL","18 Years","79 Years",{"count":54,"type":55},503,"ACTUAL","OBSERVATIONAL","The atrial fibrillation is the most frequent confusions of the heart rhythm: his preValencia increases with the age, and the investigators consider that beyond 65 years, 5 % of the population is affected by this arrhythmia. It entails a greater risk of morbidity (thromboembolic accident and cardiac insufficiency) and of cardiovascular mortality (mortality increased by a factor 1,7 - 2) independents of the causal pathology or the associated risk factors. For all these reasons, it raises a real problem of public health.",[59],"Atrial Fibrillation",[61,62],"Atrial fibrillation","Ablation","COMPLETED","2012-09-19",{"date":66,"type":67},"2012-09-20","ESTIMATED",{"date":69,"type":10},"2005-04",{"date":71,"type":55},"2010-10",{"name":5,"class":6},1]